Merck Serono Acquires Multiple Sclerosis Drug; Nixon Peabody Legal Team Advises on Deal

October 14, 2011 // // Boston, MA. Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has acquired the worldwide exclusive development and commercialization rights to PI-2301, an experimental drug for multiple sclerosis.

PI-2301 is a second-generation peptide copolymer that is thought to enhance the regulatory response of the immune system and dampen immune responses that drive autoimmune diseases such as multiple sclerosis. Merck will evaluate the product for autoimmune diseases including multiple sclerosis. The drug was originally developed by Peptimmune, the Cambridge, MA–based peptide therapeutics firm.

Nixon Peabody LLP served as Merck Serono’s legal counsel. The team was led by global business & transactions and life sciences partner Chris Keefe and bankruptcy & financial restructuring practice group leader Victor Milione. Patents group partner Mark FitzGerald also worked on the deal.



comments powered by Disqus

Franchise News Room »

News By Industry »

Featured Opportunities

BirthdayPak is an award-winning marketing platform that brings local upscale businesses together with their best customers.
la Madeleine
Things don't get much better than breakfast at la Madeleine--unless, of course, it's lunch or dinner.
Join the national insurance restoration service franchise that specializes in fire, mold, and water damage clean up. PuroClean offers a low investment
Old Chicago Pizza & Taproom
Do you love Old Chicago? Are you an experienced entrepreneur trying to find your next success story? Then you’re in the right place.
Quaker Steak & Lube®
Founded in 1974 in Sharon, PA, the award-winning casual dining restaurant chain has expanded over 55 locations throughout the United States and Canada
Share This Page

Subscribe to Franchising Express

A Franchise Update Media Production
Franchise Update Media
P.O. Box 20547
San Jose, CA 95160
PH. (408) 402-5681
In Loving Memory Of Timothy Gardner (1987-2014)

Copyright © 2001 - 2018.
All Rights Reserved.